1. Topical treatment with a mu opioid receptor agonist alleviates corneal allodynia and corneal nerve sensitization in mice
- Author
-
William Rostène, Laurence Bodineau, José-Alain Sahel, M. C. Acosta, Elodie Reboussin, Christophe Baudouin, Fanny Joubert, Annabelle Réaux-Le Goazigo, Darine Fakih, Claire Gaveriaux-Ruff, Stéphane Mélik-Parsadaniantz, Adrian Guerrero-Moreno, Juana Gallar, Institut de la Vision, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Ecole Supérieure de Biotechnologie de Strasbourg (ESBS), Université de Strasbourg (UNISTRA), Universidad Miguel Hernández [Elche] (UMH), Consejo Superior de Investigaciones Científicas [Spain] (CSIC), Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO), Fondation Ophtalmologique Adolphe de Rothschild [Paris], University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'ophtalmologie [CHU Ambroise Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Gestionnaire, Hal Sorbonne Université, Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (France), Agence Nationale de la Recherche (France), European Commission, and Fondation de France
- Subjects
0301 basic medicine ,Male ,Enkephalin ,genetic structures ,[SDV]Life Sciences [q-bio] ,Receptors, Opioid, mu ,Administration, Ophthalmic ,Pharmacology ,Corneal Diseases ,Cornea ,chemistry.chemical_compound ,Trigeminal ganglion ,Mice ,0302 clinical medicine ,Opioid receptor ,Eye Pain ,Chronic pain ,General Medicine ,3. Good health ,Analgesics, Opioid ,Electrophysiology ,[SDV] Life Sciences [q-bio] ,DAMGO ,Nociception ,Allodynia ,030220 oncology & carcinogenesis ,μ-opioid receptor ,medicine.symptom ,medicine.drug_class ,RM1-950 ,03 medical and health sciences ,medicine ,Animals ,Corneal pain ,Inflammation ,business.industry ,Enkephalin, Ala(2)-MePhe(4)-Gly(5) ,medicine.disease ,eye diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,chemistry ,nervous system ,Therapeutics. Pharmacology ,sense organs ,business - Abstract
Corneal pain is considered to be a core symptom of ocular surface disruption and inflammation. The management of this debilitating condition is still a therapeutic challenge. Recent evidence supports a role of the opioid system in the management of corneal nociception. However, the functional involvement of the mu opioid receptor (MOR) underlying this analgesic effect is not known. We first investigated the expression of the MOR in corneal nerve fibers and trigeminal ganglion (TG) neurons in control mice and a mouse model of corneal inflammatory pain. We then evaluated the anti-nociceptive and electrophysiological effects of DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol] enkephalin), a MOR-selective ligand. MOR immunoreactivity was detected in corneal nerve fibers and primary afferent neurons of the ophthalmic branch of the TG of naive mice. MOR expression was significantly higher in both structures under conditions of inflammatory corneal pain. Topical ocular administration of DAMGO strongly reduced both the mechanical (von Frey) and chemical (capsaicin) corneal hypersensitivity associated with inflammatory ocular pain. Repeated instillations of DAMGO also markedly reversed the elevated spontaneous activity of the ciliary nerve and responsiveness of corneal polymodal nociceptors that were observed in mice with corneal pain. Finally, these DAMGO-induced behavioral and electrophysiological responses were totally blunted by the topical application of naloxone methiodide, an opioid receptor antagonist. Overall, these results provide evidence that topical pharmacological MOR activation may constitute a therapeutic target for the treatment of corneal pain and improve corneal nerve function to alleviate chronic pain., This work was supported by the Sorbonne Université and the Institut National de la Santé et de la Recherche Médicale, the ANR, LabEx LIFESENSES (ANR-10-LABX-65), and IHU FOReSIGHT (ANR-18-IAHU-01). Fanny Joubert was supported by a Fondation de France post-doc fellowship grant. Adrian Guerrero Moreno was funded by a H2020-MSCA-ETN program (IT-DED3) (Grant Agreement 765608).
- Published
- 2020
- Full Text
- View/download PDF